Drug intelligence / Profile preview

sipagladenant

Development stage: Discontinued
Lead developer: Kyowa Kirin
Modality: Small Molecules
Administration: Oral

Overview

KW-6356 (sipagladenant) is a selective, non-xanthine antagonist and inverse agonist of the adenosine A2A receptor. Developed by Kyowa Kirin for the treatment of Parkinson's disease, it was designed as a second-generation A2A receptor antagonist with higher affinity and selectivity compared to earlier agents. The drug demonstrated efficacy in improving motor symptoms both as monotherapy and as adjunctive therapy with levodopa in Phase 2 clinical trials for Parkinson’s disease. Despite promising results regarding safety and efficacy in these studies, development was discontinued by Kyowa Kirin[1][3][4][5][6].

Other names: sipagladenantKW-6356KW6356KW 6356

Targets

ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on sipagladenant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sipagladenant.

Explore the full profile